Literature DB >> 28724122

Association Between Patient Age and Lymph Node Positivity in Thin Melanoma.

Andrew J Sinnamon1, Madalyn G Neuwirth1, Pratyusha Yalamanchi1, Phyllis Gimotty2, David E Elder3, Xiaowei Xu3, Rachel R Kelz1, Robert E Roses1, Emily Y Chu4, Michael E Ming4, Douglas L Fraker1, Giorgos C Karakousis1.   

Abstract

Importance: More than half of all new melanoma diagnoses present as clinically localized T1 melanoma, yet sentinel lymph node biopsy (SLNB) is controversial in this population given the overall low yield. Guidelines for SLNB have focused on pathologic factors, but patient factors, such as age, are not routinely considered.
Objectives: To identify indicators of lymph node (LN) metastasis in thin melanoma in a large, generalizable data set and to evaluate the association between patient age and LN positivity. Design, Setting, and Participants: A retrospective cohort study using the National Cancer Database, an oncology database representing patients from more than 1500 hospitals throughout the United States, was performed (2010-2013). Data analysis was conducted from October 1, 2016, to January 15, 2017. A total of 8772 patients with clinical stage I 0.50 to 1.0 mm thin melanoma undergoing wide excision and surgical evaluation of regional LNs were included for study. Main Outcome and Measures: The primary outcome of interest was presence of melanoma in a biopsied regional LN. Clinicopathologic factors associated with LN positivity were characterized, using logistic regression. Age was categorized as younger than 40 years, 40 to 64 years, and 65 years or older for multivariable analysis. Classification tree analysis was performed to identify high-risk groups for LN positivity.
Results: Among the study cohort (n = 8772), 333 patients had nodal metastases, for an overall positivity rate of 3.8% (95% CI, 3.4%-4.2%). A total of 4087 (54.0%) patients were women. Median age was 56 years (interquartile range [IQR], 46-67) in patients with negative LNs and 52 years (IQR, 41-61) in those with positive LNs (P < .001). In multivariable analysis, younger age, female sex, thickness of 0.76 mm or larger, increasing Clark level, mitoses, ulceration, and lymphovascular invasion were independently associated with LN positivity. In decision tree analysis, patient age was identified as an important risk stratifier for LN metastases, after mitoses and thickness. Patients younger than 40 years with category T1b tumors 0.50 to 0.75 mm, who would generally not be recommended for SLNB, had an LN positivity rate of 5.6% (95% CI, 3.3%-8.6%); conversely, patients 65 years or older with T1b tumors 0.76 mm or larger, who would generally be recommended for SLNB, had an LN positivity rate of only 3.9% (95% CI, 2.7%-5.3%). Conclusions and Relevance: Patient age is an important factor in estimating lymph node positivity in thin melanoma independent of traditional pathologic factors. Age therefore should be taken into consideration when selecting patients for nodal biopsy.

Entities:  

Mesh:

Year:  2017        PMID: 28724122      PMCID: PMC5710422          DOI: 10.1001/jamadermatol.2017.2497

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  26 in total

1.  Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma.

Authors:  Christian Kunte; Till Geimer; Jens Baumert; Birger Konz; Matthias Volkenandt; Michael Flaig; Thomas Ruzicka; Carola Berking; Monika-H Schmid-Wendtner
Journal:  Melanoma Res       Date:  2010-08       Impact factor: 3.599

2.  Vertical growth phase and positive sentinel node in thin melanoma.

Authors:  R S Oliveira Filho; L M Ferreira; L J Biasi; M M S S Enokihara; G R Paiva; J Wagner
Journal:  Braz J Med Biol Res       Date:  2003-03-07       Impact factor: 2.590

3.  Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm).

Authors:  Karyn B Stitzenberg; Pamela A Groben; Stacey L Stern; Nancy E Thomas; Thomas A Hensing; Leah B Sansbury; David W Ollila
Journal:  Ann Surg Oncol       Date:  2004-09-20       Impact factor: 5.344

4.  Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.

Authors:  Dale Han; Jonathan S Zager; Yu Shyr; Heidi Chen; Lynne D Berry; Sanjana Iyengar; Mia Djulbegovic; Jaimie L Weber; Suroosh S Marzban; Vernon K Sondak; Jane L Messina; John T Vetto; Richard L White; Barbara Pockaj; Nicola Mozzillo; Kim James Charney; Eli Avisar; Robert Krouse; Mohammed Kashani-Sabet; Stanley P Leong
Journal:  J Clin Oncol       Date:  2013-11-04       Impact factor: 44.544

5.  Importance of sentinel lymph node biopsy in patients with thin melanoma.

Authors:  Byron E Wright; Randall P Scheri; Xing Ye; Mark B Faries; Roderick R Turner; Richard Essner; Donald L Morton
Journal:  Arch Surg       Date:  2008-09

Review 6.  Sentinel Lymph Node Biopsy in Thin Cutaneous Melanoma: A Systematic Review and Meta-Analysis.

Authors:  Erin Cordeiro; Mai-Kim Gervais; Prakesh S Shah; Nicole J Look Hong; Frances C Wright
Journal:  Ann Surg Oncol       Date:  2016-03-01       Impact factor: 5.344

7.  Prediction of survival in patients with thin melanoma: results from a multi-institution study.

Authors:  Andrea Maurichi; Rosalba Miceli; Tiziana Camerini; Luigi Mariani; Roberto Patuzzo; Roberta Ruggeri; Gianfranco Gallino; Elena Tolomio; Gabrina Tragni; Barbara Valeri; Andrea Anichini; Roberta Mortarini; Daniele Moglia; Giovanni Pellacani; Sara Bassoli; Caterina Longo; Pietro Quaglino; Nicola Pimpinelli; Lorenzo Borgognoni; Daniele Bergamaschi; Catherine Harwood; Odysseas Zoras; Mario Santinami
Journal:  J Clin Oncol       Date:  2014-07-07       Impact factor: 44.544

8.  Sentinel lymph node biopsy in patients with thin melanomas.

Authors:  Roberto Cecchi; Lauro Buralli; Stefania Innocenti; Cataldo De Gaudio
Journal:  J Dermatol       Date:  2007-08       Impact factor: 4.005

9.  Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.

Authors:  M Mandalà; G L Imberti; D Piazzalunga; M Belfiglio; R Labianca; M Barberis; L Marchesi; P Poletti; L Bonomi; L Novellino; K Di Biagio; A Milesi; U Guerra; C Tondini
Journal:  Eur J Cancer       Date:  2009-06-22       Impact factor: 9.162

10.  The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.

Authors:  Karl Y Bilimoria; Andrew K Stewart; David P Winchester; Clifford Y Ko
Journal:  Ann Surg Oncol       Date:  2008-01-09       Impact factor: 5.344

View more
  10 in total

1.  Early Melanoma Nodal Positivity and Biopsy Rates Before and After Implementation of the 7th Edition of the AJCC Cancer Staging Manual.

Authors:  Chelsea Isom; Lee Wheless; Mary A Hooks; Rondi M Kauffmann
Journal:  JAMA Dermatol       Date:  2019-05-01       Impact factor: 10.282

2.  Use and Costs of Sentinel Lymph Node Biopsy in Non-Ulcerated T1b Melanoma: Analysis of a Population-Based Registry.

Authors:  Joshua N Herb; David W Ollila; Karyn B Stitzenberg; Michael O Meyers
Journal:  Ann Surg Oncol       Date:  2021-04-26       Impact factor: 5.344

3.  Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma: An International Multi-institutional Collaboration.

Authors:  Richard J B Walker; Nicole J Look Hong; Marc Moncrieff; Alexander C J van Akkooi; Evan Jost; Carolyn Nessim; Winan J van Houdt; Emma H A Stahlie; Chanhee Seo; May Lynn Quan; J Gregory McKinnon; Frances C Wright; Michail N Mavros
Journal:  Ann Surg Oncol       Date:  2022-06-08       Impact factor: 4.339

4.  Survival analysis and sentinel lymph node status in thin cutaneous melanoma: A multicenter observational study.

Authors:  Antonio Tejera-Vaquerizo; Simone Ribero; Susana Puig; Aram Boada; Sabela Paradela; David Moreno-Ramírez; Javier Cañueto; Blanca de Unamuno; Ana Brinca; Miguel A Descalzo-Gallego; Simona Osella-Abate; Paola Cassoni; Cristina Carrera; Sergi Vidal-Sicart; Antoni Bennássar; Ramón Rull; Llucìa Alos; Celia Requena; Isidro Bolumar; Víctor Traves; Ángel Pla; A Fernández-Orland; Ane Jaka; María T Fernández-Figueres; Josep M Hilari; Pol Giménez-Xavier; Ricardo Vieira; Rafael Botella-Estrada; Concepción Román-Curto; Lara Ferrándiz; Nicolás Iglesias-Pena; Carlos Ferrándiz; Josep Malvehy; Pietro Quaglino; Eduardo Nagore
Journal:  Cancer Med       Date:  2019-06-18       Impact factor: 4.452

5.  Risk factors for positive sentinel lymph node, lymphatic or hematogenous dissemination over time in patients with cutaneous melanoma.

Authors:  Alexandra S Berghe; Gheorghe Cobzac; George Dindelegan; Simona C Șenilă; Corina I Baican; Carolina M Solomon; Liliana Rogojan; Daniel C Leucuța; Tudor C Drugan; Sorana D Bolboacă
Journal:  Exp Ther Med       Date:  2021-05-05       Impact factor: 2.447

6.  Short-course neoadjuvant in situ vaccination for murine melanoma.

Authors:  Taylor J Aiken; David Komjathy; Matthew Rodriguez; Ashley Stuckwisch; Arika Feils; Vladimir Subbotin; Jen Birstler; Stephen D Gillies; Alexander L Rakhmilevich; Amy K Erbe; Paul M Sondel
Journal:  J Immunother Cancer       Date:  2022-01       Impact factor: 13.751

Review 7.  Sentinel lymph node biopsy in melanoma: beyond histologic factors.

Authors:  Michael J Carr; Federico A Monzon; Jonathan S Zager
Journal:  Clin Exp Metastasis       Date:  2021-06-08       Impact factor: 5.150

8.  Metastases risk in thin cutaneous melanoma: prognostic value of clinical-pathologic characteristics and mutation profile.

Authors:  Antonio G Richetta; Virginia Valentini; Federica Marraffa; Giovanni Paolino; Piera Rizzolo; Valentina Silvestri; Veronica Zelli; Anna Carbone; Cinzia Di Mattia; Stefano Calvieri; Pasquale Frascione; Pietro Donati; Laura Ottini
Journal:  Oncotarget       Date:  2018-08-14

9.  Prognostic significance of regression and mitotic rate in head and neck cutaneous melanoma.

Authors:  Elizabeth Kim; Isaac Obermeyer; Nathan Rubin; Samir S Khariwala
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-12-16

10.  Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction.

Authors:  Eric D Whitman; Vadim P Koshenkov; Brian R Gastman; Deri Lewis; Eddy C Hsueh; Ho Pak; Thomas P Trezona; Robert S Davidson; Michael McPhee; J Michael Guenther; Paul Toomey; Franz O Smith; Peter D Beitsch; James M Lewis; Andrew Ward; Shawn E Young; Parth K Shah; Ann P Quick; Brian J Martin; Olga Zolochevska; Kyle R Covington; Federico A Monzon; Matthew S Goldberg; Robert W Cook; Martin D Fleming; David M Hyams; John T Vetto
Journal:  JCO Precis Oncol       Date:  2021-09-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.